IncidenceRisk FactorsFollow-Up StudiesRetrospective StudiesCohort StudiesProspective StudiesTreatment OutcomeTime FactorsNeoplasms, Second PrimaryProportional Hazards ModelsRecurrenceSurvival AnalysisGraft vs Host DiseaseTransplantation, HomologousRegistriesTransplantation ConditioningAge DistributionRisk AssessmentKaplan-Meier EstimateSurvival RateHematopoietic Stem Cell TransplantationInfant, NewbornRiskHematologic NeoplasmsDisease-Free SurvivalMinnesotaCord Blood Stem Cell TransplantationUnited StatesPrognosisPrevalenceMultivariate AnalysisWisconsinSex DistributionSwedenJapanPopulation SurveillancePoisson DistributionNeoplasmsPostoperative ComplicationsDisease ProgressionImmunosuppressive AgentsPrecursor Cell Lymphoblastic Leukemia-LymphomaAge FactorsDenmarkLongitudinal StudiesCombined Modality TherapyVidarabineLife TablesTissue DonorsBreast NeoplasmsNeoplasm Recurrence, LocalSurvivorsAntilymphocyte SerumUnrelated DonorsAcute DiseaseBusulfanModels, StatisticalConfidence IntervalsMyeloablative AgonistsOdds RatioNeoplasms, Radiation-InducedSiblingsRadiotherapyNetherlandsEpidemiologic MethodsBone Marrow TransplantationRemission InductionRegression AnalysisTaiwanAntineoplastic Combined Chemotherapy ProtocolsMyelodysplastic SyndromesOsteonecrosisLeukemia, Myeloid, AcuteTreatment FailureHistocompatibility TestingDiabetes Mellitus, Type 1Whole-Body IrradiationLogistic ModelsItalyUterine Cervical NeoplasmsPredictive Value of TestsSeasonsMyocardial InfarctionComorbidityPeripheral Blood Stem Cell TransplantationGraft SurvivalPregnancySirolimusCause of DeathMass ScreeningHistocompatibilityScandinaviaFinlandChronic DiseaseDouble-Blind MethodTacrolimusHIV InfectionsInfectionKidney Failure, ChronicSeverity of Illness Index